tetracosahexaenoic acid: RN given refers to (all-Z)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
tetracosahexaenoic acid : Any C24 straight-chain fatty acid containing six C=C double bonds. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 6439582 |
| SCHEMBL ID | 28597 |
| MeSH ID | M0261951 |
| Synonym |
|---|
| 81247-23-6 |
| tetracosahexaenoic acid, (all-z)- |
| tetracosahexaenoic acid |
| LMFA01030804 |
| 2e,4e,6e,8e,10e,12e-tetracosahexaenoic acid |
| c24:6n-12,14,16,18,20,22 |
| (2e,4e,6e,8e,10e,12e)-tetracosa-2,4,6,8,10,12-hexaenoic acid |
| SCHEMBL28597 |
| tetracosahexaenic acid |
| fa(24:6) |
Tetracosahexaenoic acid (24:6ω-3) is an intermediate in the conversion of 18:3 ω to 22:6 ω in mammals.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Tetracosahexaenoic acid (24:6ω-3) is an intermediate in the conversion of 18:3ω-3 to 22:6ω-3 in mammals. " | ( Exogenous tetracosahexaenoic acid modifies the fatty acid composition of human primary T lymphocytes and Jurkat T cell leukemia cells contingent on cell type. Burdge, GC; Calder, PC; Fielding, BA; Irvine, NA; Lillycrop, KA; Miles, EA; Von Gerichten, J; West, AL, 2023) | 2.76 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " By building on nearly three decades of research primarily in cell culture and oral dosing studies, recent evidence presented focuses on in vivo kinetic modelling and compound-specific isotope abundance studies in rodents and humans that have been instrumental in expanding our knowledge of the pathway." | ( Updates to the n-3 polyunsaturated fatty acid biosynthesis pathway: DHA synthesis rates, tetracosahexaenoic acid and (minimal) retroconversion. Bazinet, RP; Metherel, AH, 2019) | 0.74 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (23.53) | 18.2507 |
| 2000's | 2 (11.76) | 29.6817 |
| 2010's | 9 (52.94) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.49) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (5.88%) | 5.53% |
| Reviews | 1 (5.88%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 15 (88.24%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||